Fairscale Capital, LLC Beam Therapeutics Inc. Transaction History
Fairscale Capital, LLC
- $113 Billion
- Q2 2024
A detailed history of Fairscale Capital, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Fairscale Capital, LLC holds 50 shares of BEAM stock, worth $1,274. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50Holding current value
$1,274% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BEAM
# of Institutions
230Shares Held
73.6MCall Options Held
283KPut Options Held
233K-
Farallon Capital Management LLC San Francisco, CA7.91MShares$202 Million0.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$201 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$195 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.63MShares$194 Million1.63% of portfolio
-
Arch Venture Management, LLC Chicago, IL5.44MShares$139 Million74.72% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.79B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...